A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers-Reference-Cited by-同舟云学术

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

Published:2016-07-13 Issue:1 Volume:7 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Ferrari Anthony,Vincent-Salomon Anne,Pivot Xavier,Sertier Anne-Sophie,Thomas Emilie,Tonon Laurie,Boyault Sandrine,Mulugeta Eskeatnaf,Treilleux Isabelle,MacGrogan Gaëtan,Arnould Laurent,Kielbassa Janice,Le Texier Vincent,Blanché Hélène,Deleuze Jean-François,Jacquemier Jocelyne,Mathieu Marie-Christine,Penault-Llorca Frédérique,Bibeau Frédéric,Mariani Odette,Mannina Cécile,Pierga Jean-Yves,Trédan Olivier,Bachelot Thomas,Bonnefoi Hervé,Romieu Gilles,Fumoleau Pierre,Delaloge Suzette,Rios Maria,Ferrero Jean-Marc,Tarpin Carole,Bouteille Catherine,Calvo Fabien,Gut Ivo Glynne,Gut Marta,Martin Sancha,Nik-Zainal Serena,Stratton Michael R.,Pauporté Iris,Saintigny Pierre,Birnbaum Daniel,Viari Alain,Thomas Gilles

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms12222.pdf

Reference69 articles.

1. Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001).

2. Prat, A. et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J. Natl Cancer Inst. 106, dju152 (2014).

3. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).

4. Marty, M. et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23, 4265–4274 (2005).

5. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

2. Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review;Journal of Modern Oncology;2024-07-03

3. The mitochondrial calcium uniporter: Balancing tumourigenic and anti‐tumourigenic responses;The Journal of Physiology;2024-06-10

4. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy;The Breast;2024-06

5. Mutational landscape of inflammatory breast cancer;Journal of Translational Medicine;2024-04-18